Key result
Metformin is linked to ~10% lower all-cause and CV mortality in patients with cardiac disease.
Why the study?
Whether metformin reduces all-cause mortality, cardiovascular mortality, and incidence of cardiovascular events in patients with cardiac diseases remains inconclusive.
Does metformin reduce mortality and cardiovascular events in patients with pre-existing cardiovascular diseases?
Meta-Analysis (n=61,704)
Does metformin reduce mortality and cardiovascular events in patients with pre-existing cardiovascular diseases?
Metformin is associated with reduced all-cause and cardiovascular mortality, as well as lower incidence of coronary revascularization and heart failure, in patients with pre-existing cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
May support metformin consideration in cardiac patients; extends observational data but leaves randomized confirmation open.
Background and Purpose Whereas whether metformin reduce all-cause, cardiovascular mortality, and incidence of cardiovascular events in patients with cardiac diseases remains inconclusive. Experimental Approach PubMed and Embase were searched up to May 2020 with a registration in PROSPERO (CRD42020189905) were collected. This article includes randomized controlled trials (RCT) and cohort studies. Hazard ratio (HR) with 95% CI was pooled across various trials by a random-effects model. Risk of bias was accounted as per Cochrane and Newcastle-Ottawa Scale (NOS) guidelines. Key Results This article enrolled 48 articles (1999-2020) for qualitative synthesis and identified 26 articles (33 studies in total, 61,704 patients) for final quantitative synthesis. Compared with non-metformin control, metformin is associated with reduced all-cause mortality (HR: 0.90; 95% CI: 0.83, 0.98; P = 0.01), cardiovascular mortality (HR: 0.89; 95% CI: 0.85, 0.94; P < 0.0001), incidence of coronary revascularization (HR: 0.79; 95% CI: 0.64, 0.98; P = 0.03), and heart failure (HR: 0.90; 95% CI: 0.87, 0.94; P < 0.0001) in patients with cardiac diseases, whereas metformin is not associated with reduced incidence of myocardial infarction (HR: 0.97; 95% CI: 0.80, 1.17; P = 0.73), angina (HR: 0.29; 95% CI: 0.04, 2.35; P = 0.25), and stroke (HR: 0.95; 95% CI: 0.78, 1.16; P = 0.59). Conclusion and Implications Metformin reduces all-cause mortality, cardiovascular mortality, incidence of coronary revascularization, and heart failure of patients with cardiac diseases, whereas metformin is not associated with reduced incidence of myocardial infarction, angina, and stroke.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted a meta-analysis in Cardiac diseases (n=61,704). Metformin vs. Non-metformin control was evaluated on All-cause mortality (HR 0.90, 95% CI 0.83-0.98, p=0.01). Metformin was associated with reduced all-cause mortality (HR 0.90; 95% CI 0.83-0.98; P=0.01) and cardiovascular mortality in patients with cardiac diseases compared to non-metformin control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: